PART I . Overview We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. Our lead pipeline program is NKX019, a chimeric antig...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001787400-26-000006 | EDGAR | 89K words |
| 2025-03-26 | 2024-12-31 | 0000950170-25-045262 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034735 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008523 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004095 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015517 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274304 | EDGAR | 64K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178964 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071455 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123395 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096186 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056980 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062091 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040953 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021277 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023845 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016892 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009693 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001787400-26-000008 | EDGAR | 1K words |
| 2026-03-25 | 0001787400-26-000005 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274261 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178949 | EDGAR | — |
| 2025-06-06 | 0000950170-25-082717 | EDGAR | — |
| 2025-05-14 | 0000950170-25-071399 | EDGAR | — |
| 2025-03-26 | 0000950170-25-045231 | EDGAR | — |
| 2024-11-07 | 0000950170-24-123340 | EDGAR | — |
| 2024-08-13 | 0000950170-24-096163 | EDGAR | — |
| 2024-07-16 | 0000950170-24-083761 | EDGAR | — |
99 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001787400 |
| Ticker | NKTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nkartatx.com |
| Listed | 2020-07-10 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report